Coatings with tunable amine density

ABSTRACT

Molecules or salts thereof are provided, having the structure in Formula I,wherein n2 and n4 are the same or different and are independently 1, 2, or 3, and n3 is 1 to 20;X is oxygen, nitrogen, or sulfur;wherein R1, R2, R3, R4, R5, R6, and R7 are as described herein.Methods are also provided for the synthesis of and use of the provided molecules in applications for diagnostic testing.

CROSS-REFERENCE

This application is a continuation of U.S. patent application Ser. No.16/348,485, filed on May 8, 2019, which is a U.S. National Phase ofInternational Application No. PCT/US2017/060724, filed on Nov. 8, 2017,which claims the benefit of U.S. Provisional Application No. 62/419,864,filed Nov. 9, 2016, each of which is incorporated herein by reference inits entirety.

SUMMARY OF THE INVENTION

Disclosed herein are molecules or salts thereof, having the structure:

-   -   wherein R¹ and R² can be the same or different and can be        independently hydrogen, alkyl, alkenyl, aryl, heteroaryl,        alkynyl, arylalkyl, arylalkenyl, haloalkyl, cycloalkyl,        sulfonamidyl, acyl, or —CO₂R⁸, wherein R⁸ is alkyl, alkenyl,        aryl, arylalkyl, arylalkenyl, haloalkyl, cycloalkyl,        cycloalkylalkyl, or arylcycloalkylalkyl; or wherein R¹ and R²        and the N to which they are bound can form a ring; or wherein at        least one of R¹ or R² can comprise a nucleoside, nucleotide,        polynucleotide, peptide, peptoid, saccharide, polysaccharide,        aptamer, or antibody or fragment thereof;    -   R³, oriented from N to X, can be alkyl, heteroalkyl,        amino-substituted alkyl, amino-substituted heteroalkyl,        amidoalkyl, amidoheteroalkyl, amino-substituted        amidoheteroalkyl, each optionally substituted with an alkyl,        heteroalkyl, amino-substituted alkyl, amino-substituted        heteroalkyl, amidoalkyl, amidoheteroalkyl, or amino-substituted        amidoheteroalkyl ; or wherein R³ can be —(CR⁹R¹⁰CR¹¹R¹²)_(n)—,        wherein n can be 1 to 100, and R⁹, R¹⁰, R¹¹, and R¹² can be the        same or different and can be independently hydrogen, halo,        alkyl, heteroalkyl, amino-substituted alkyl, amino-substituted        heteroalkyl, amidoalkyl, amidoheteroalkyl, amino-substituted        amidoheteroalkyl; or wherein R³ can be

-   -   -   wherein n² and n⁴ can be the same or different and can be            independently 1, 2, or 3, and n³ can be 1 to 20, or wherein            R³ can be a polymer comprising alkyl, heteroalkyl,            amino-substituted alkyl, aminoheteroalkyl, and amidoalkyl;

    -   X can be O, NR¹³, or S, wherein R¹³ is hydrogen or alkyl;

    -   R⁴, oriented from X to C, can be alkyl, alkylether, and        alkylthioether, wherein each of alkyl, alkylether, and        alkylthioether can be optionally substituted with hydroxyl,        thiol, amino, or halo;

    -   R⁵, R⁶, and R⁷ can be the same or different and can be        independently hydrogen, alkyl, silyl, or siloxy; and

wherein at least one of R⁵, R⁶, or R⁷ optionally further comprises asolid phase.

In some aspects the molecules or salts of structure I can comprise asolid phase. In some aspects, the solid phase can comprise a siliconatom.

Also disclosed herein are molecules or salts thereof, having thestructure:

-   -   wherein R¹ and R² can be the same or different and can be        independently hydrogen, alkyl, alkenyl, aryl, heteroaryl,        alkynyl, arylalkyl, arylalkenyl, haloalkyl, cycloalkyl,        sulfonamidyl, acyl, or —CO₂R⁸, wherein R⁸ can be alkyl, alkenyl,        aryl, arylalkyl, arylalkenyl, haloalkyl, cycloalkyl,        cycloalkylalkyl, or arylcycloalkylalkyl; or wherein R¹ and R²        and the N to which they are bound can form a ring; or wherein at        least one of R¹ or R² can comprise a nucleoside, nucleotide,        polynucleotide, peptide, peptoid, saccharide, polysaccharide,        aptamer, or antibody or fragment thereof;    -   R³, oriented from NR¹R² to NH can be alkyl, heteroalkyl,        amino-substituted alkyl, amino-substituted heteroalkyl,        amidoalkyl, amidoheteroalkyl, amino-substituted        amidoheteroalkyl, each optionally substituted with an alkyl,        heteroalkyl, amino-substituted alkyl, amino-substituted        heteroalkyl, amidoalkyl, amidoheteroalkyl, or amino-substituted        amidoheteroalkyl; or wherein R³ can be —(CR⁷R⁸CR⁹R¹⁰)_(n)—        wherein n can be 1 to 100, and R⁷, R⁸, R⁹, and R¹⁰ can be the        same or different and can be hydrogen, halo, alkyl, heteroalkyl,        amino-substituted alkyl, amino-substituted heteroalkyl,        amidoalkyl, amidoheteroalkyl, amino-substituted        amidoheteroalkyl; or wherein R³ can be

-   -   -   wherein n² and n⁴ can be the same or different and can be            independently 1, 2, or 3, and n³ can be 1 to 20; or wherein            R³ can be a polymer or dendrimer comprising alkyl,            heteroalkyl, amino-substituted alkyl, amino-substituted            heteroalkyl, amidoalkyl, and amino-substituted amidoalkyl,            amidoheteroalkyl, or amino-substituted amidoheteroalkyl;

    -   R⁴, R⁵, and R⁶ can be the same or different and can be        independently hydrogen, alkyl, silyl, or siloxy;

    -   (*) is a carbon center, wherein said carbon center can be in an        R-configuration or S-configuration; and

wherein at least one of R⁴, R⁵, or R⁶ optionally further comprises asolid phase.

In some aspects, the carbon center can be in an R-configuration. In someaspects, the carbon center can be in an S-configuration. In some aspectsare molecules or salts comprising a solid phase. In some aspects thesolid phase can comprise a silicon atom. In some aspects are moleculesof structure II, wherein R³ can comprise alkyl, aminoheteroalkyl,polyamidoaminoalkyl, or polyaminoalkyl.

Also disclosed herein are molecules or salts thereof, having thestructure:

wherein:

-   n¹ can be 1, 2, 3, 4, 5, 6, or 7;-   n² and n³ can be the same or different and can be independently    about 1 to about 1000;-   R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵,    R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ can be the same or different and can be    hydrogen, alkyl, alkenyl, aryl, heteroaryl, alkynyl, arylalkyl,    arylalkenyl, haloalkyl, cycloalkyl, sulfonamidyl, acyl, or —CO₂R²⁴,    wherein R²⁴ is alkyl, alkenyl, aryl, arylalkyl, arylalkenyl,    haloalkyl, cycloalkyl, cycloalkylalkyl, or arylcycloalkylalkyl; or    wherein R¹ and R² and the N to which they are bound, R³ and R⁴ and    the N to which they are bound, R⁵ and R⁶ and the N to which they are    bound, R⁷ and R⁸ and the N to which they are bound, R⁹ and R¹⁰ and    the N to which they are bound, R¹¹ and R¹² and the N to which they    are bound, R¹³ and R¹⁴ and the N to which they are bound, R¹⁵ and    R¹⁶ and the N to which they are bound, R¹⁷ and R¹⁸ and the N to    which they are bound, and R¹⁹ and R²⁰ and the N to which they are    bound independently optionally form a ring;-   R³, R⁴, and R⁵ can be the same or different and are independently    hydrogen, alkyl, silyl, or siloxy;-   (*), (**), and (***) are carbon centers, wherein said carbon centers    can be independently in an R-configuration or S-configuration, or    can be achiral centers;-   (****) is a second carbon center, wherein said second carbon center    can be in an R-configuration or an S-configuration; and    wherein at least one of R²¹, R²², or R²³ optionally further    comprises a solid phase.

In some aspects, a carbon center can be in an R-configuration. In someaspects, the carbon center can be in an S-configuration. In some aspectsthe molecules or salts of structures III, IV, V, or VI can comprise asolid phase. In some aspects, the solid phase can comprise a siliconatom.

In some aspects are methods of synthesizing molecules or salts ofstructure I, II, III, IV, V, or VI. In some aspects, the method cancomprise forming an oxygen-silicon covalent bond between a solidsubstrate and a first molecule. In some aspects, the first molecule cancomprise a silicon at a first end and an epoxide, isocyanate, orthioisocyanate at a second end. In some aspects, the method can furthercomprise forming a Y-carbon covalent bond between a carbon atom of anepoxide, isocyanate, or thioisocyanate and a second molecule comprisingan amino group. In some aspects, Y can be nitrogen, oxygen, sulfur, orselenium. In some aspects, the epoxide, isocyanate, or isothiocyanateand silicon can be linked by a group comprising an alkyl, alkylether, oralkylthioether, wherein each of alkyl, alkylether, or alkylthioether isoptionally substituted with hydroxyl, thiol, amino, or halo. In someaspects, the second molecule can be an alkylamine, heteroalkylamine,amino-substituted alkylamine, amino-substituted heteroalkylamine,amidoalkylamine, amidoheteroalkylamine, or amino-substitutedamidoheteroalkylamine, each optionally substituted with an alkyl,heteroalkyl, amino-substituted alkyl, amino-substituted heteroalkyl,amidoalkyl, amidoheteroalkyl, or amino-substituted amidoheteroalkyl. Insome aspects, forming an oxygen-silicon bond can comprise a depositionreaction. In some aspects, a deposition reaction can be performed in thegas phase. In some aspects, the deposition reaction can comprise achemical vapor deposition reaction. In some aspects, the chemical vapordeposition reaction can occur at an elevated temperature. In someaspects, the elevated temperature can be at least about 100° C., 110°C., 120° C., 130° C., 140° C., or 150° C. In some aspects, the firstmolecule can be 3-glycidoxypropyltrimethoxysilane (GPTMS) or anyreactive aminosilane. In some aspects, the second molecule can beethylenediamine (EDA), (ethylenedioxy)bis(ethylamine) (EDBA), tris(2-aminoethyl)amine (TAEA), polyamidoamine (PAMAM), or polyallylamine(PAAm). In some aspects, PAAm can have an average molecular weight offrom about 1 KDa to about 100 KDa. In some aspects, the second moleculecan have a boiling point of from about 100° C., to 300° C. In someaspects, the method can further comprise coupling the amino group to aprotected amino acid or salt thereof. In some aspects, the protectedamino acid salt can be a tert-butyl carbamate (Boc)- or9-fluorenylmethyl carbamate (Fmoc)-protected amino acid. In someaspects, the amino acid can be glycine.

In some aspects are amino coatings comprising two or more of any one ofthe molecules or salts of structures I, II, III, IV, V, or VI. In someaspects are methods of tuning the amino group density of the aminocoating. In some aspects are arrays comprising two or more of any one ofthe molecules or salts of structures I, II, III, IV, V, or VI. In someaspects, the array can comprise at least 2 of any one of the moleculesor salts of structures I, II, III, IV, V, or VI. In some aspects, thearray can comprise a density of said amino groups from about 1×10¹⁰groups per cm² to about 1×10¹⁴ groups per cm². In some aspects,molecules can be stereoenriched or racemtates. In some aspects,molecules or salts can have an enantiomeric excess of at least about10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,99%, or 100%. In some aspects, at least one of the molecules or saltscan form a coating. In some aspects, the coating has a thickness of fromabout 1 angstrom to about 25 angstroms. In some aspects, molecules ortheir salts are cross-linked. In some aspects, arrays can furthercomprise instructions for their use.

In some aspects are methods for making an array. In some aspects, makingan array can comprise associating the molecule or salt of structure I,II, III, IV, V, or VI with a substrate. In some aspects, making an arraycan comprise any of the methods disclosed herein for making molecules orsalts of structures I, II, III, IV, V, or VI. In some aspects, the arraycomprises a density of amino group about 1×10¹⁰ groups per cm2 to about1×10¹⁴ groups per cm2. In some aspects are methods comprising tuning thedensity of said amino groups on said array. In some aspects are kits. Insome aspects, kits comprise the molecules of structures I, II, III, IV,V, or VI. In some aspects, kits comprise a binding moiety. In someaspects, a binding moiety can be an antibody. In some aspects, a bindingmoiety can emit a signal. In some aspects are methods of making kits. Insome aspects, methods of making kits can comprise forming a kit with themolecules or salts of structures I, II, III, IV, V, VI. In some aspectsare molecules or salts made by the process of the methods disclosedherein. In some aspects are arrays made by the process of the methodsdisclosed herein.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications herein areincorporated by reference in their entireties. In the event of aconflict between a term herein and a term in an incorporated reference,the term herein controls.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features described herein are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the features described herein will be obtained byreference to the following detailed description that sets forthillustrative examples, in which the principles of the features describedherein are utilized, and the accompanying drawings of which:

FIG. 1. depicts a GPTMS-PAAm surface coating, prepared by chemical vapordeposition. GPTMS is 3-glycidoxypropyltrimethoxysilane.

FIG. 2. depicts a GPTMS-TAEA surface coating prepared by chemical vapordeposition.

FIG. 3. depicts the reactive amine density of GPTMS-TAEA surfacecoatings prepared by either solution phase reaction or chemical vapordeposition.

FIG. 4. Depicts the reactive amine density of GPTMS-TEA coating comparedto a GPTMS coating.

FIG. 5. depicts a GPTMS-HMDA linker prepared by chemical vapordeposition

FIG. 6. Depicts reactive amine densities for GPTMS-linked EDA, TAEA,PAMAM, and PAAm amino coatings. Also depicted are reactive aminedensities for aminosilane coatings APTES, APDEMS, and APDIPES.

FIG. 7 reactive amine densities for GPTMS-TAEA linkers with chemicalvapor deposition performed at 100, 125, and 150 degrees Celcius.

FIG. 8 depicts reactive amine densities fro GPTMS-linked EDA, TAEA, andPAAm surface coatings.

FIG. 9 depicts water contact angle and thickness properties forGPTMS-linked-EDA and Boc-Gly surface coatings at different depositionconditions.

FIG. 10 depicts surface amine densities of GPTMS-TAEA, GPTMS-PAAm, andAPTES surface coatings.

FIG. 11 depicts the use of a diluent to tune the reaction of formingsecond coating layer.

FIG. 12 depicts the experimental conditions for use of a diluent to tunethe reaction of forming a second coating layer.

FIG. 13 depicts thickness and water contact angle analysis of aminocoatings produced with a diluent in the formation of the second coatinglayer.

FIG. 14 depicts reactive amine density of amino coatings under variousreaction conditions.

FIG. 15 depicts the use of a molecular array for immunosignaturing.

FIG. 16 depicts the arrangement of features on a molecular array.

FIG. 17 depicts substrate characteristics, coating compositions,deposition methods, and analytical characterization methods.

FIG. 18 depicts a scheme for peptide synthesis.

FIG. 19 depicts protected amino acids.

FIG. 20 depicts aminosilane coating structures.

FIG. 21 depicts why surface properties control important.

FIG. 22 depicts thickness and water contact angle analysis of aminocoatings.

FIG. 23 depicts a scheme for a reactive amine density assay.

FIG. 24 depicts an amine density analysis of amino coatings.

FIG. 25 depicts an AFM analysis of the smoothness of deposition of aminocoatings.

FIG. 26 depicts an experimental process for side chain deprotection.

FIG. 27 depicts an outline of a peptide synthesis process.

FIG. 28 depicts a thickness analysis of peptide-functionalized aminocoatings.

FIG. 29 depicts thickness and XPS analysis of amino coatings.

FIG. 30 depicts a scheme for peptide synthesis, amine capping, andMALDI-MS analysis.

FIG. 31 depicts a scheme for peptide synthesis, amine capping, andMALDI-MS analysis.

FIG. 32 depicts a thickness analysis of amino coatings.

FIG. 33 depicts a thickness analysis of amino coatings.

FIG. 34 depicts procedures for surface preparation for MALDI-MSanalysis.

FIG. 35 depicts a MALDI-MS analysis of array coatings.

FIG. 36 depicts a purity analysis of peptides synthesized on aminocoatings.

FIG. 37 depicts a MALDI-MS analysis of array coatings.

FIG. 38 depicts a purity analysis of peptides synthesized on aminocoatings.

FIG. 39 depicts a MALDI-MS analysis of array coatings.

FIG. 40 depicts a purity analysis of peptides synthesized on aminocoatings.

FIG. 41 depicts a MALDI-MS analysis of array coatings.

FIG. 42 depicts a purity analysis of peptides synthesized on aminocoatings.

FIG. 43 depicts a summary of amino coating properties.

DETAILED DESCRIPTION

Several aspects are described below with reference to exampleapplications for illustration. It should be understood that numerousspecific details, relationships, and methods are set forth to provide afull understanding of the features described herein. One having ordinaryskill in the relevant art, however, will readily recognize that thefeatures described herein can be practiced without one or more of thespecific details or with other methods. The features described hereinare not limited by the illustrated ordering of acts or events, as someacts can occur in different orders and/or concurrently with other actsor events. Furthermore, not all illustrated acts or events are requiredto implement a methodology in accordance with the features describedherein.

The terminology used herein is for the purpose of describing particularcases only and is not intended to be limiting. As used herein, thesingular forms “a”, “an” and “the” are intended to include the pluralforms as well, unless the context clearly indicates otherwise.Furthermore, to the extent that the terms “including”, “includes”.“having”, “has”. “with”, or variants thereof are used in either thedetailed description and/or the claims, such terms are intended to beinclusive in a manner similar to the term “comprising”.

The term “about” or “approximately” can mean within an acceptable errorrange for the particular value as determined by one of ordinary skill inthe art, which will depend in part on how the value is measured ordetermined, i.e. the limitations of the measurement system. For example,“about” can mean within 1 or more than 1 standard deviation.Alternatively, “about” can mean a range of up to 20%, up to 10%, up to5%, or up to 1% of a given value. Alternatively, particularly withrespect to biological systems or processes, the term can mean within anorder of magnitude, within 5-fold, and more preferably within 2-fold, ofa value. Where particular values are described in the application andclaims, unless otherwise stated the term “about” meaning within anacceptable error range for the particular value should be assumed. Theterm “about” has the meaning as commonly understood by one of ordinaryskill in the art. In some embodiments, the term “about” refers to ±10%.In some embodiments, the term “about” refers to ±5%.

Overview

Detecting and diagnosing immune-mediated disorders, including autoimmunedisorders, infections, and cancer, is challenging, with patients havinga difficult time receiving an accurate or correct diagnosis. In manyinstances, patients are often misdiagnosed with other autoimmuneconditions because of the closely related nature of these diseases. Thedisclosure, in one aspect, relates to compounds, methods, and devicesthat identify differential patterns of peripheral-blood antibody bindingto a array-bound molecular library. Differential binding of patientsamples to the array results in specific binding patterns or signaturesindicative of the disease state of the patient. These binding signaturescan accurately determine or diagnose a disease activity, including butnot limited to autoimmune disease activity, infectious disease activity,cancer activity, and diabetes disease activity. The identification ofsuch differential binding activity, or signature, is referred to as“immunosignaturing.” Synthesized peptide libraries have been commonlyused for antibody binding characterization. However, protein androbotically printed peptide arrays have been cost-prohibitive and insitu synthesized peptide arrays have suffered from lack of scalability,poor reproducibility and low production quality. The technologiesherein, in one aspect, will enable reliable, low cost, and scaleablemethods for construction and use of arrays for immunosignaturing assays.

In some embodiments, arrays with chemical libraries produced by thetechnologies disclosed herein are used for immune-based diagnosticassays, for example, immunosignature assays. In one aspect, using apatient's antibody repertoire from a drop of blood bound to the arrays,a fluorescence binding profile image of the bound array providesufficient information to identify and classify a disease state. Thearrays disclosed herein incorporate analytical measurements capabilitywithin each synthesized array using orthogonal analytical methodsincluding ellipsometry, mass spectrometry, and fluorescence. Thesemeasurements enable longitudinal qualitative and quantitative assessmentof array synthesis performance.

In some embodiments, detection of antibody binding on a peptide arrayposes some challenges that can be addressed by the technologiesdisclosed herein. The technologies disclosed herein address twopotential shortcomings of using molecular arrays to profile antibodybinding. First, non-specific antibody binding on a array is minimized bycoating the solid support with a moderately hydrophilic monolayercomprising, in some embodiments, polyethylene glycol. In someembodiments, the hydrophilic monolayer is homogeneous. Second,synthesized library are linked to the surface using a linker that movesthe peptide away from the surface of the solid support so that thepeptide may be presented to an antibody in an unhindered orientation.The technologies disclosed herein include such linkers, which, in oneaspect, connect chemical libraries to solid supports, including, in someaspects, arrays for immunosignaturing.

Molecules or linkers can also be known as coatings when, for example,formed on a solid support. The technologies herein relate to methods forsynthesizing amino-containing coatings, which can be furtherfunctionalized at the amino group. The technologies herein furtherrelate to methods for tuning the density of amino groups in coatings.Tuning the density of amino groups in coatings has the advantage ofproviding flexibility for optimizing the binding characteristics ofcoatings, and functionalized coatings, to binding moieties. Formation ofcoatings onto a solid phase can be achieved by solution phase or gasphase reactions. Solid phases can comprise native oxide, thermal oxide,or siloxane surfaces. Solid phases can comprise BTMSE.

Further disclosed herein are arrays comprising the molecules disclosedherein. In some aspects, the arrays comprise a nucleoside, nucleotide,polynucleotide, peptide, peptoid, saccharide, aptamer, or antibody orfragment thereof chemically bound to the linker. In one aspect, thenucleoside, nucleotide, polynucleotide, peptide, peptoid, saccharide,aptamer, or antibody or fragment thereof comprise a chemical library. Insome embodiments, the array is a peptide array. In some aspects, thepeptide array is synthesized in situ.

One of the major deficiencies of in situ synthesized peptide arrays hasbeen the inability to directly measure purity of the synthesized peptidefeatures. In some embodiments, the technologies include qualitative insitu mass spectrometry of synthesized peptides directly from solidsupport. Mass spectrometry is performed by incorporating a gas-phasecleavable linker between the solid support and the synthesized peptidesso that cleavage of the peptide is done without diffusion from the arrayfeature. Following peptide cleavage, Matrix-Assisted Laser DesorptionIonization (MALDI) mass spectrometry is performed directly on the solidsupport by applying a thin aerosol matrix layer and subsequentlyfocusing the MALDI laser on individual peptide features to acquire amass spectrum for each synthesized peptide. Qualitative in situ MALDImass spectrum from a peptide array feature produced using thephotolithographic synthesis approach are also included in the methodsand devices described herein. Other analyses known to those of skill inthe art may also be used to quantify and/or qualify the fidelity of thein situ synthesis process disclosed herein.

Definitions

The terms “attach”, “bind”, “couple”, and “link” are usedinterchangeably and refer to covalent interactions (e.g., by chemicallycoupling), or non-covalent interactions (e.g., ionic interactions,hydrophobic interactions, hydrogen bonds, hybridization, etc.). Theterms “specific”, “specifically”, or specificity” refer to thepreferential recognition, contact, and formation of a stable complexbetween a first molecule and a second molecule compared to that of thefirst molecule with any one of a plurality of other molecules (e.g.,substantially less to no recognition, contact, or formation of a stablecomplex between the first molecule and any one of the plurality of othermolecules). For example, two molecules may be specifically attached,specifically bound, specifically coupled, or specifically linked.Furthermore, “binding” may refer to either a specific interaction, suchas the interaction of an antibody with an epitope, or it may refer to anon-specific interaction.

Nomenclature

Unless otherwise indicated, the term “alkyl” as employed herein alone oras part of another group can include both straight and branched chainhydrocarbons, containing, for instance, 1 to 20 carbons, 1 to 10carbons, or 1 to 8 carbons, in the normal chain, such as methyl, ethyl,propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl,heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl,undecyl, dodecyl, the various branched chain isomers thereof, and thelike as well as such groups including 1 to 4 substituents such as halo,for example F, Br, Cl or I or CF₃, alkyl, alkoxy, aryl, aryloxy,aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl,cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxyl, hydroxyalkyl,acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy,aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido,alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl,trihaloalkyl and/or alkylthio.

Unless otherwise indicated, the term “cycloalkyl” as employed hereinalone or as part of another group can include saturated or partiallyunsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groupscontaining 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (orbicycloalkyl) and tricyclic alkyl (tricycloalkyl), containing a total of3 to 20 carbons forming the ring and which may be fused to 1 or 2aromatic rings as described for aryl, which includes cyclopropyl,cyclobuyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyland cyclododecyl, cyclohexenyl, adamantyl, and the like, any of whichmay be optionally substituted with 1 to 4 substituents such as halogen,alkyl, alkoxy, hydroxyl, aryl, aryloxy, arylalkyl, cycloalkyl,hyroxyalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino,amino, nitro, cyano, thiol and/or alkylthio and/or any of thesubstituents for alkyl.

The term “alkanoyl” as used herein alone or as part of another group canrefer to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term “alkenyl” as used herein by itselfor as part of another group can refer to straight or branched chainradicals of, for instance, 2 to 20 carbons in the normal chain, whichinclude one to six double bonds in the normal chain, such as vinyl,2-propenyl, 3-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl,2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl,3-undecenyl, 4-dodecenyl, 4, 8, 12-tetradecatrienyl, and the like, andwhich may be optionally substituted with 1 to 4 substituents, namely,halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl,cycloalkyl, amino, hydroxyl, heteroaryl, cycloheteroalkyl,alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol,alkylthio and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term “alkynyl” as used herein by itselfor as part of another group can refer to straight or branched chainradicals of 2 to 20 carbons in the normal chain, which include onetriple bond in the normal chain, such as 2-propynyl, 3-butynyl,2-butynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl,4-heptynyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyland the like, and which may be optionally substituted with 1 to 4substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl,alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl,cycloheterolalkyl, hydroxyl, alkanoylamino, alkylamido,arylcarbonylamino, nitro, cyano, thiol, and/or any of the alkylsubstitutents set out herein.

The term “halogen” or “halo” as used herein alone or as part of anothergroup can refer to chlorine, bromine, fluorine, and iodine.

Unless otherwise indicated, the term “aryl” as employed herein alone oras part of another group can refer to monocyclic and biclic aromaticgroups containing 6 to 10 carbons in the ring portion (such as phenyl ornaphthyl including 1-naphthyl and 2-naphthyl) and may optionally includeone to three additional rings fused to a carbocyclic ring or aheterocyclic ring (such as aryl, cycloalkyl, heteroaryl orcycloheteroalkyl rings) and may be optionally substituted throughavailable carbon atoms with 1, 2, or 3 groups selected from hydrogen,halo, halolalkyl, alkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl,trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloheteroalkyl,cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy,aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl,heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxyl, nitro,cyano, amino, substituted amino wherein the amino can include 1 or 2substituents (which are alkyl, aryl or any of the other aryl compoundsmentioned in the definitions), thiol, alkylthio, arylthio,heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl,arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl,aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonyloxy,arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino orarylsulfonaminocarbonyl and/or any of the alkyl substituents set outherein.

Unless otherwise indicated, the term “amino-substituted” as employedherein alone or as part of another group can refer to a chemical grouphaving from 1 to 10 amino groups substituted thereon.

Unless otherwise indicated, the term “alkylthio” (also known as“thioalkyl”) or “arylthio” (also known as “thioaryl”) as employed hereinalone or as part of another group can include any of the above alkyl oraryl groups linked to a sulfur atom.

Unless otherwise indicated, the term “selenoalkyl” as employed hereinalone or as part of another group can include any of the above alkylgroups linked to a selenium atom.

Unless otherwise indicated, the term “alkylamino” or “arylamino” asemployed herein alone or as part of another group can include any of theabove alkyl or aryl groups linked to a nitrogen atom.

Unless otherwise indicated, the term “acyl” as employed herein by itselfas part of another group, as defined herein, can refer to an organicradical linked to a carbonyl

group; examples of acyl groups include any of the R groups attached to acarbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl,cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term “cycloheteroalkyl” as used hereinalone or as part of another group can refer to a 5-, 6-, or 7-memberedsaturated or partially unsaturated ring which can include 1 to 2heteroatoms such as nitrogen, oxygen and/or sulfur, linked through acarbon atom or a heteroatom, where possible, optionally via the linker(CH₂)_(r) (where r is 1, 2, or 3).

Unless otherwise indicated, the term “heteroaryl” as used herein aloneor as part of another group can refer to a 5- or 6-membered aromaticring which can include 1, 2, 3 or 4 heteroatoms such as nitrogen, oxygenor sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl orcycloheteroalkyl ring, and includes possible N-oxides. The heteroarylgroup may optionally include 1 to 4 substituents such as any of thesubstituents set out above for alkyl.

Unless otherwise indicated, the term “heteroalkyl” as used herein aloneor as part of another group can refer to an alkyl group, as definedherein, which can include 1, 2, 3, or 4 heteroatoms such as nitrogen,oxygen or sulfur. The heteroalkyl group may optionally include 1 to 4substituents such as any of the substituents set out above for alkyl.

All stereoisomers of compounds are contemplated, either in admixture orin pure or substantially pure form. Compounds can have asymmetric carboncenters at any of the carbon atoms including any one of the Rsubstituents. Compounds can be either optically active or opticallyinactive. Asymmetric carbon centers can be independently in an R- orS-configuration. As defined herein asymmetric carbons are carbons thatare a stereogenic center. Consequently, compounds of structures I, IA,or II can exist in enantiomeric or diastereomeric forms or in mixturesthereof. Enantiomeric mixtures can exist with an enantiomeric excess of10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,99%, 99.5% or 100%. Diastereomeric mixtures can exist with adiastereomeric ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1,10:1, 20:1, 50:1, 100:1, or 500:1. The processes for preparation of themolecules disclosed herein can utilize racemates, enantiomers ordiastereomers as starting materials. When diastereomeric or enantiomericproducts are prepared, they can be separated by conventional methods,for example, by chromatographic or fractional crystallization.

A polynucleotide, as used herein, can be any type of nucleic acidmolecule, including DNA, RNA, a hybridization thereof, or anycombination thereof. For example, a polynucleotide can be cDNA, genomicDNA, mRNA, tRNA, rRNA, or microRNA.

A peptide, polypeptide, or protein can be contemplated to include anyfragments thereof, in particular, immunologically detectable fragments.A peptide can be contemplated to include an α-peptide, a β-peptide, or aγ-peptide.

Methods

Methods disclosed herein can include synthesizing coatings on solidsupports. Characteristics of coatings prepared by the methods disclosedherein can be analyzed by various methods understood by person of skillin the art. Methods of analysis can include, ellipsometry, water contactangle (WCA), X-ray photoelectron spectroscopy (XPS), atomic forcemicroscopy (AFM), colorimetry, mass-spectrometry, including MALDI-MS,and the like.

In some embodiments, forming coatings can comprise coupling anaminosilane to a substrate. In some embodiments, the aminosilane cancomprise 3-aminopropyltriethoxysilane (APTES),3-aminopropylmethyldiethoxysilane (APDEMS), or3-aminopropyldiisopropylethoxysilane (APDIPES).

In some embodiments, forming coatings can comprise a first stepcomprising forming a first coating layer. In some embodiments, the firststep can comprise forming an oxygen-silicon bond between a soldsubstrate and a first molecule. In some embodiments, the first moleculecan comprise a silicon at a first end and an epoxide, isocyanate, orthioisocyanate at a second end. In some embodiments, the first step canbe performed in solution phase or in gas phase. In some embodiments,forming coatings can further comprise a second step comprising couplinga second molecule to the epoxide, isocyante, or thioisocyanate of thefirst molecule to form a second coating layer. Coatings, as used herein,can be understood to encompass both single layer coatings and coatingscomprising a first layer and a second layer. In some embodiments, thesecond molecule can have a boiling point of about 100° C., 110° C., 120°C., 130° C., 140° C., 150° C., 160° C., 170° C., 180° C., 190° C., 200°C., 210° C., 220° C., 230° C. 240° C., 250° C., 260° C. 270° C., 280° C.290° C., 300° C. 310° C., 320° C. 330° C., 340° C., or 350° C. In someembodiments, the second step can comprise using a diluent. In someembodiments, a diluent can be an alcohol. In some embodiments, thealcohol can be ethanol, 1-propanol, 2-propanol (also known asisopropanol), 1-butanol, 2-butanol, tert-butanol, 1-pentanol,2-pentanol, 3-pentanol, 3-methylbutan-1-ol (also known as isoamyl orisopentyl alcohol), 2-methylbutan-1-ol, 2,2-dimethylpropan-1-ol (alsoknown as neopentyl alcohol), 3-methylbutan-2-ol, or 2-methylbutan-2-ol(also known as tert-amyl alcohol).

In some embodiments, formation of a coating can be accomplished by adeposition reaction. In some embodiments, the deposition reaction can bea chemical vapor deposition reaction. In some embodiments, coatings canbe characterized by their water contact angle. In some embodiments,coatings can have a water contact angle of about 10°, 20°, 30°, 40°,50°, 60°, 70°, 80°, 90°, 100°, 110°, 120°, 130°, 140°, 150°, or 160°. Insome embodiments, coatings can have a contact angle from about about 10°to about 120°. In some embodiments, coatings can have a water contactangle from about 40° to about 90°. In some embodiments, coatings can becharacterized by their thickness. In some embodiments, thickness can bemeasured by ellipsometry. In some embodiments, coatings can have athickness of about 0.5 angstroms (Å), 0.6 Å, 0.7 Å, 0.8 Å, 0.9 Å, 1 Å, 2Å, 3 Å, 4 Å, 5 Å, 6 Å, 7 Å, 8 Å, 9 Å, 10 Å, 1 Å, 12 Å, 13 Å, 14 Å, 15 Å,16 Å, 17 Å, 18 Å, 19 Å, 20 Å, 25 Å, 30 Å, 35 Å, 40 Å, 45 Å, 50 Å, 60 Å,70 Å, 80 Å, 90 Å, or 100 Å. In some embodiments, coatings can have athickness of from about 1 Å to about 10 Å. In some embodiments, coatingscan have a thickness of from about 5 Å to about 7 Å. In someembodiments, coatings can be characterized by their smoothness. In someembodiments, coating smoothness can be measured by AFM. In someembodiments, coatings can have a smoothness of a root mean square ofroughness (R_(q)) of about 0.10 nm, 0.11 nm, 0.12 nm, 0.13 nm, 0.14 nm,0.15 nm, 0.16 nm, 0.17 nm, 0.18 nm, 0.19 nm, 0.20 nm, 0.21 nm, 0.22 nm,0.23 nm, 0.24 nm, 0.25 nm, 0.26 nm, 0.27 nm, 0.28 nm, 0.29 nm, or 0.30nm. In some embodiments, coatings can have an R_(q) of from about 0.1 nmto about 0.3 nm. In some embodiments, coatings can have an Rq of fromabout 0.2 to about 0.25 nm. In some embodiments, coatings can have adensity of amino groups of about 1×10⁹, 1×10¹⁰, 1×10¹¹, 1×10¹², 1×10¹³,1×10¹⁴, or 1×10¹⁵ amino groups per square centimeter.

In some embodiments, coatings can be coupled at the amine to a targetanalyte to form a target analyte-functionalized coating. In someembodiments, a target analyte can be a peptide. A peptide can be fromabout 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids. In some embodiments,peptides can comprise a library of peptides. In some embodiments,peptides can have protected side chains. In some embodiments, peptideside chains can be protected as benzyl ethers. In some embodiments, acoating can be coupled to a peptide by stepwise coupling of each ofamino acid of the peptide.

Some embodiments comprise functionalizing an amino coating. Aminocoatings can be functionalized by coupling the amino groups of the aminocoating to molecules. A molecule can be a building block. In someembodiments, coupling comprises: coupling of an amino group to thecarboxylic acid of a first building block. In some embodiments, abuilding block can comprise a carboxylic acid and a protected amine. Insome embodiments, a building block can be an N-protected amino acid. Insome embodiments, the protected amino acid can comprise a Boc-protectedamine or an Fmoc-protected amine. In some embodiments, coupling canfurther comprise deprotection of the coupled building block. In someembodiments, coupling can further comprise coupling of the amino groupof the deprotected first building block to the carboxylic acid of asecond building block. In some embodiments, functionalizing of an aminocoating can comprise iterative couplings to 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,or 100 building blocks. In some embodiments, protected building blockscan be protected amino acids.

In some embodiments, functionalizing an amino coating can furthercomprise performing a capping step after any one of the describedcoupling steps. Capping can comprise reacting amino groups with areagent to form a protected, or capped, amino group. Capping cancomprise reacting amino groups that were not consumed in the precedingcoupling reaction. Capping reagents can comprise acetic anhydride,acetyl chloride, acetyl fluoride, or an acylglycine. In some aspects,the capping step can form an alkylamine, arylamine, acetamide,carbamate, phthalimide, enamine, sulfonamide, or N-protected amino acid.In some aspects, the N-protected amino acid can be an N-acyl-protectedamino acid. In some aspects, the protected amino acid can be acetylglycine.

In some embodiments, forming coatings can comprise a first stepcomprising forming a first coating layer. In some embodiments, the firststep can comprise forming an oxygen-silicon bond between a soldsubstrate and a first molecule. In some embodiments, the first moleculecan comprise a silicon at a first end and an epoxide, isocyanate, orthioisocyanate at a second end. In some embodiments, the first step canbe performed in solution phase or in gas phase. In some embodiments,forming coatings can further comprise a second step comprising forming asecond coating layer. In some embodiments, forming said second coatinglayer can comprise a chemical vapor deposition reaction.

Supports/Substrates/Solid Phases

The present disclosure provides solid supports (also known as solidphases, substrates, or supports). The nature and geometry of a supportor substrate can depend upon a variety of factors, including the type ofarray (e.g., one-dimensional, two-dimensional or three-dimensional).Generally, a substrate can be composed of any material which will permitcoupling of a nucleoside, nucleotide, polynucleotide, peptide, peptoid,saccharide, aptamer, or antibody or fragment thereof, which will notmelt or degrade under the conditions used to couple said nucleoside,nucleotide, polynucleotide, peptide, peptoid, saccharide, aptamer, orantibody or fragment thereof to said solid support. A solid support canbe composed of any material which will permit coupling of a targetanalyte, and/or other moiety at one or more discrete regions and/ordiscrete locations within the discrete regions. A solid support can becomposed of any material which will permit washing or physical orchemical manipulation without dislodging a target analyte or bindingmoiety from the solid support.

A substrate may take a variety of configurations ranging from simple tocomplex, depending on the intended use of the array. Thus, a substratecan have an overall slide or plate configuration, such as a rectangularor disc configuration. A standard microplate configuration can be used.In some embodiments, the surface may be smooth or substantially planar,or have irregularities, such as depressions or elevations. For example,the substrates of the presently disclosed subject matter can include atleast one surface on which a pattern of recombinant virion microspotscan be coupled or deposited. In some instances, a substrate may have arectangular cross-sectional shape, having a length of from about 10-200mm, 40-150 mm, or 75-125 mm; a width of from about 10-200 mm, 20-120 mm,or 25-80 mm, and a thickness of from about 0.01-5.0 mm, 0.1-2 mm, or 0.2to 1 mm.

A support may be organic or inorganic; may be metal (e.g., copper orsilver) or non-metal; may be a polymer or nonpolymer; may be conducting,semiconducting or nonconducting (insulating); may be reflecting ornonreflecting; may be porous or nonporous; etc. A solid support asdescribed above can be formed of any suitable material, includingmetals, metal oxides, semiconductors, polymers (particularly organicpolymers in any suitable form including woven, nonwoven, molded,extruded, cast, etc.), silicon, silicon oxide, and composites thereof.

Suitable materials for use as substrates include, but are not limitedto, polycarbonate, gold, silicon, silicon oxide, silicon oxynitride,indium, tantalum oxide, niobium oxide, titanium, titanium oxide,platinum, iridium, indium tin oxide, diamond or diamond-like film,acrylic, styrene-methyl methacrylate copolymers, ethylene/acrylic acid,acrylonitrile-butadiene-styrene (ABS), ABS/polycarbonate.ABS/polysulfone, ABS/polyvinyl chloride, ethylene propylene, ethylenevinyl acetate (EVA), nitrocellulose, nylons (including nylon 6, nylon6/6, nylon 6/6-6, nylon 6/9, nylon 6/10, nylon 6/12. nylon 11 and nylon12), polyacrylonitrile (PAN), polyacrylate, polycarbonate, polybutyleneterephthalate (PBT), poly(ethylene) (PE) (including low density, linearlow density, high density, cross-linked and ultra-high molecular weightgrades), poly(propylene) (PP), cis and trans isomers of poly(butadiene)(PB), cis and trans isomers of poly (isoprene), polyethyleneterephthalate) (PET), polypropylene homopolymer, polypropylenecopolymers, polystyrene (PS) (including general purpose and high impactgrades), polycarbonate (PC), poly(epsilon-caprolactone) (PECL or PCL),poly(methyl methacrylate) (PMMA) and its homologs, poly(methyl acrylate)and its homologs, poly(lactic acid) (PLA), poly(glycolic acid),polyorthoesters, poly(anhydrides), nylon, polyimides,polydimethylsiloxane (PDMS), polybutadiene (PB), polyvinylalcohol (PVA),polyacrylamide and its homologs such as poly(N-isopropyl acrylamide),fluorinated polyacrylate (PFOA), poly(ethylene-butylene) (PEB),poly(styrene-acrylonitrile) (SAN), polytetrafluoroethylene (PTFE) andits derivatives, polyolefin plastomers, fluorinated ethylene-propylene(FEP), ethylene-tetrafluoroethylene (ETFE), perfluoroalkoxyethylene(PFA), polyvinyl fluoride (PVF), polyvinylidene fluoride (PVDF),polychlorotrifluoroethylene (PCTFE),polyethylene-chlorotrifluoroethylene (ECTFE), styrene maleic anhydride(SMA), metal oxides, glass, silicon oxide or other inorganic orsemiconductor material (e.g., silicon nitride), compound semiconductors(e.g., gallium arsenide, and indium gallium arsenide), and combinationsthereof.

Examples of well-known solid supports include polypropylene,polystyrene, polyethylene, dextran, nylon, amylases, glass, natural andmodified celluloses (e.g., nitrocellulose), polyacrylamides, agarosesand magnetite. In some instances, the solid support can be silica orglass because of its great chemical resistance against solvents, itsmechanical stability, its low intrinsic fluorescence properties, and itsflexibility of being readily functionalized. In one embodiment, thesubstrate can be glass, particularly glass coated with nitrocellulose,more particularly a nitrocellulose-coated slide (e.g., FAST slides).

In some embodiments, the support can be planar. In some instances, thesupport can be spherical. In some instances, the support can be a bead.In some instances, a support can be magnetic. In some instances, amagnetic solid support can comprise magnetite, maghemite, FePt, SrFe,iron, cobalt, nickel, chromium dioxide, ferrites, or mixtures thereof.In some instances, a support can be nonmagnetic. In some embodiments,the nonmagnetic solid support can comprise a polymer, metal, glass,alloy, mineral, or mixture thereof. In some instances a nonmagneticmaterial can be a coating around a magnetic solid support. In someinstances, a magnetic material may be distributed in the continuousphase of a magnetic material. In some embodiments, the solid supportcomprises magnetic and nonmagnetic materials. In some instances, a solidsupport can comprise a combination of a magnetic material and anonmagnetic material. In some embodiments, the magnetic material is atleast about 5, 10, 20, 30, 40, 50, 60, 70, or about 80% by weight of thetotal composition of the solid support. In some embodiments, the beadsize can be quite large, on the order of 100-900 microns or in somecases even up to a diameter of 3 mm. In other embodiments, the bead sizecan be on the order of 1-150 microns. The average particle diameters ofbeads can be in the range of about 2 μm to several millimeters, e.g.,diameters in ranges having lower limits of 2 μm, 4 μm, 6 μm, 8 μm, 10μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 150μm, 200 μm, 300 μm, or 500 μm, and upper limits of 20 μm, 30 μm, 40 μm,50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 150 μm, 200 μm, 300 μm, 500μm, 750 μm, 1 mm, 2 mm, or 3 mm.

In some embodiments, the support can comprise an array. In someembodiments, the array comprises a target analyte. In some embodiments,the target analyte comprises a nucleoside, a nucleotide, apolynucleotide, a peptide, a peptoid, a saccharide, a polysaccharide, anaptamer, or an antibody or fragment thereof. In some embodiments, thetarget analyte comprises a library of target analytes.

In some embodiments, an array comprises a library of molecules. In someembodiments, the array can comprise at least about 100, 1000, 10,000,100,000, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, or 10¹⁵molecules per 1 cm². In some embodiments, a molecule can comprise asequence of monomers. In some embodiments, the sequence of monomers cancomprise a sequence of amino acids. In some embodiments, a feature canbe a region on a substrate from about 0.5 microns to about 200 micronsin diameter. In some embodiments, the array can have a plurality offeatures. In some embodiments, the center-to-center distance betweenfeatures can be from about 1 micron to about 300 microns. In someembodiments, the array can comprise at least about 1,000, 10,000,100,000, 200,000, 300,000, 400,000, or 500,000, 1 million, 2 million, 3million, 4 million, or 8 million features per 1 cm². In someembodiments, at least about 40% of the molecules in the library aredistinct. In some embodiments, at least about 50% of the molecules inthe library are distinct. In some embodiments, at least about 60% of themolecules in the library are distinct. In some embodiments, at leastabout 70% of the molecules in the library are distinct. In someembodiments, at least about 80% of the molecules in the library aredistinct. In some embodiments, at least about 90% of the molecules inthe library are distinct. In some embodiments, at least 50% of themolecules in the library are at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, or 100monomers in length. In some embodiments, at least 50% of the moleculesin the library are at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, or 100 monomers inlength. In some embodiments, the library comprises a median monomerlength of about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 30, 40, 50, 60, 70, 80, 90, or 100 monomers. In someembodiments, the array can comprise at least 10,000, 50,000, 100,000,200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000,10⁶, or 10⁷ sequentially distinct library molecules. In someembodiments, the array substrate can be selected from wafers, slides,and beads. In some embodiments, the library can be an in-situsynthesized chemical library. In some embodiments, the molecules can bepolynucleotides, peptides, peptoids, or poly saccharides.

Binding Moiety

An analyte binding moiety, also referred to as a binding moiety (ordomain) can be the region, molecule, domain, portion, fragment, ormoiety that binds to a target analyte. Thus, a binding moiety confersthe ability to bind or specifically bind to given target. A bindingmoiety can be a nucleic acid molecule or can be proteinaceous. Bindingmoieties include, but are not limited to, RNAs DNAs, RNA-DNA hybrids,small molecules (e.g., drugs or metabolites), aptamers, polypeptides,proteins, antibodies, viruses, virus particles, cells, fragmentsthereof, and combinations thereof.

In some embodiments, a binding moiety can be a polypeptide, a protein,or any fragment thereof. In some embodiments, a polypeptide or proteincan be an engineered or recombinant polypeptide or protein. In someembodiments, a binding moiety is an antibody or fragment thereof. Anantibody can be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA and IgY),class (IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, IgA₂), subclass or modified versionthereof. Antibodies may include complete immunoglobulins or fragmentsthereof. An antibody fragment can refer to one or more fragments of anantibody that retains the ability to specifically bind to a targetmolecule, such as an antigen.

In some embodiments, a binding moiety can be an aptamer. An aptamer isan isolated nucleic acid molecule that can bind with high specificityand affinity to a target analyte, such as a protein. An aptamercomprises a three dimensional structure held in certain conformation(s)that provide chemical contacts to specifically bind a given target. Insome embodiments, a binding moiety is small molecule. For example, asmall molecule can be a macrocyclic molecule, an inhibitor, a drug, orchemical compound. In some embodiments, a binding moiety is a cell. Forexample, a binding moiety can be an inact cell, a cell treated with acompound (e.g, a drug), a fixed cell, a lysed cell, or any combinationthereof.

Detection Methods

Detection methods for detecting bound binding moieties can includephotometric and non-photometric means. In some embodiments, such methodsprocess includes a method to detect and measure absorbance,fluorescence, refractive index, polarization or light scattering. Theseinclude direct and/or indirect means to measure such parameters. Methodsinvolving fluorescence include fluorescent tagging in immunologicalmethods such as ELISA or sandwich assay. Methods involving refractiveindex include surface Plasmon resonance (SPR), grating coupled methods(e.g., sensors uniform grating couplers, wavelength-interrogated opticalsensors (WIOS) and chirped grating couplers), resonant minor andinterferometric techniques. Methods involving polarization includeellipsometry. Light scattering methods may also be used. Other means fortagging and/or separating and/or detecting can also include magneticmeans. Magnetic resonance imaging (MRI), or gas phase ion spectrometrymay all be used.

Non-photometric methods of detection include, without limitation,magnetic resonance imaging, gas phase ion spectrometry, atomic forcemicroscopy and multipolar coupled resonance spectroscopy. Magneticresonance imaging (MRI) is based on the principles of nuclear magneticresonance (NMR), a spectroscopic technique used by scientists to obtainmicroscopic chemical and physical information about molecules. Gas phaseion spectrometers include mass spectrometers, ion mobility spectrometersand total ion current measuring devices.

Binding assays can also be useful, e.g., for identifying disease relatedantibodies (binding moieties) that interact with the target analytesdescribed herein. For example, antibodies or other molecules that bindtarget analytes can be identified in binding assays. Binding assays caninvolve, but are not limited to, use of isolated polypeptides, crudeextracts, or cell-based assays. In some embodiments the assays describedherein can be used to a) identify subjects whose have a first disease ora second disease; (b) assess the impact of an disease therapy; and (c)monitor disease progression.

Binding assays can involve contacting a target analyte with a samplecomprising a binding moiety (antibody) and allowing sufficient time forthe molecule and test agents to form a binding complex. Any bindingcomplexes formed can be detected using any of a number of establishedanalytical techniques. Binding assays include, but are not limited to,methods that measure co-precipitation or co-migration on non-denaturingSDS-polyacrylamide gels, co-migration on Western blots, enzyme linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometricassay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay,fluorescence activated cells sorting (FACS), or fluorescence resonanceenergy transfer (FRET).

Diagnostics

The methods and apparatus disclosed herein can be used to screen forvarious diseases or conditions, including an alteration in the state ofthe body or of some of the organs, interrupting or disturbing theperformance of the functions and/or causing symptoms such as discomfort,dysfunction, distress, or even death to the person afflicted or those incontact with the person. A disease or condition can also include adistemper, ailing, ailment, amalady, disorder, sickness, illness,complain, interdisposition and/or affectation.

For example, samples containing binding moieties from a diseased animalcan be simultaneously screened for the binding moieties' ability tointeract with an array. These interactions can be compared to those ofsamples from individuals that are not in a disease state, not presentingsymptoms of persons in the disease state, or presenting symptoms of thedisease state. For example, the levels of binding moieties in samplesfrom a diseased animal can be simultaneously determined. These levelscan be compared to those of samples from individuals that are not in adisease state, not presenting symptoms of persons in the disease state,or presenting symptoms of the disease state.

The methods, kits, and compositions described herein can be used inmedical diagnostics, drug discovery, molecular biology, immunology andtoxicology. Arrays can be used for large scale binding assays innumerous diagnostic and screening applications. The multiplexedmeasurement of quantitative variation in levels of large numbers oftarget analytes (e.g., proteins) allows the recognition of patternsdefined by several to many different target analytes. The multiplexedidentification of large numbers of interactions between target analytesand binding moieties allows for the recognition of binding andinteraction patterns defined by several to many different interactionsbetween target analytes and binding moieties. Many physiologicalparameters and disease-specific patterns can be simultaneously assessed.One embodiment involves the separation, identification andcharacterization of proteins present in a biological sample. Forexample, by comparison of disease and control samples, it is possible toidentify disease specific target analytes. These target analytes can beused as targets for drug development or as molecular markers of disease.Substrate-bound molecules of the present invention may also be used assolid phase filtration devices, wherein capture agents are attached tothe surface.

In some embodiments, methods can be methods for diagnosing or detectinga disease or condition such as a cancer, inflammatory disease, immunedisease, autoimmune disease, cardiovascular disease, neurologicaldisease, infectious disease, metabolic disease, or a perinatalcondition. For example, the disease or condition can be a tumor,neoplasm, or cancer. The cancer can be, but is not limited to, breastcancer, ovarian cancer, lung cancer, colon cancer, hyperplastic polyp,adenoma, colorectal cancer, high grade dysplasia, low grade dysplasia,prostatic hyperplasia, prostate cancer, melanoma, pancreatic cancer,brain cancer (such as a glioblastoma), hematological malignancy,hepatocellular carcinoma, cervical cancer, endometrial cancer, head andneck cancer, esophageal cancer, gastrointestinal stromal tumor (GIST),renal cell carcinoma (RCC) or gastric cancer. The colorectal cancer canbe CRC Dukes B or Dukes C-D. The hematological malignancy can be B-CellChronic Lymphocytic Leukemia, B-Cell Lymphoma-DLBCL, B-CellLymphoma-DLBCL-germinal center-like, B-Cell Lymphoma-DLBCL-activatedB-cell-like, or Burkitt's lymphoma. The disease or condition can also bea premalignant condition, such as Barrett's Esophagus. The disease orcondition can also be an inflammatory disease, immune disease, orautoimmune disease. For example, the disease may be inflammatory boweldisease (IBD). Crohn's disease (CD), ulcerative colitis (UC), pelvicinflammation, vasculitis, psoriasis, diabetes, autoimmune hepatitis,Multiple Sclerosis, Myasthenia Gravis, Type I diabetes, RheumatoidArthritis, Psoriasis. Systemic Lupus Erythematosis (SLE), Hashimoto'sThyroiditis, Grave's disease. Ankylosing Spondylitis Sjogrens Disease.CREST syndrome. Scleroderma, Rheumatic Disease, organ rejection, PrimarySclerosing Cholangitis, or sepsis. The disease or condition can also bea cardiovascular disease, such as atherosclerosis, congestive heartfailure, vulnerable plaque, stroke, or ischemia. The cardiovasculardisease or condition can be high blood pressure, stenosis, vesselocclusion or a thrombotic event. The disease or condition can also be aneurological disease, such as Multiple Sclerosis (MS), Parkinson'sDisease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar disorder,depression, autism, Prion Disease, Pick's disease, dementia, Huntingtondisease (HD), Down's syndrome, cerebrovascular disease, Rasmussen'sencephalitis, viral meningitis, neuropsychiatric systemic lupuserythematosus (NPSLE), amyotrophic lateral sclerosis, Creutzfeldt-Jacobdisease, Gerstmann-Straussler-Scheinker disease, transmissiblespongiform encephalopathy, ischemic reperfusion damage (e.g., stroke),brain trauma, microbial infection, or chronic fatigue syndrome. Thecondition may also be fibromyalgia, chronic neuropathic pain, orperipheral neuropathic pain. The disease or condition may also be aninfectious disease, such as a bacterial, viral or yeast infection. Forexample, the disease or condition may be Whipple's Disease, PrionDisease, cirrhosis, methicillin-resistant Staphylococcus aureus. HIV,hepatitis, syphilis, meningitis, malaria, tuberculosis, or influenza.The disease or condition can also be a perinatal or pregnancy relatedcondition (e.g., preeclampsia or preterm birth), zika virus, denguefever, flavivirus, or a metabolic disease or condition, such as ametabolic disease or condition associated with iron metabolism.

In some embodiments, methods are methods for diagnosing or detecting anautoimmune disorder. In some embodiments, methods can be methods fordetermining a disease or condition or the progression of a disease orcondition. Non-limiting examples of disorder associated with the immunesystem can include: autoimmune disorders, inflammatory diseases, HIV,rheumatoid arthritis, diabetes mellitus type 1, systemic lupuserythematosus, scleroderma, multiple sclerosis, severe combinedimmunodeficiency (SCID), DiGeorge syndrome, ataxia-telangiectasia,seasonal allergies, perennial allergies, food allergies, anaphylaxis,mastocytosis, allergic rhinitis, atopic dermatitis, Parkinson's,Alzheimer's, hypersplenism, leukocyte adhesion deficiency, X-linkedlymphoproliferative disease, X-linked agammaglobulinemia, selectiveimmunoglobulin A deficiency, hyper IgM syndrome, autoimmunelymphoproliferative syndrome, Wiskott-Aldrich syndrome, chronicgranulomatous disease, common variable immunodeficiency (CVID),hyperimmunoglobulin E syndrome, Hashimoto's thyroiditis.

Kits

Also provided are kits that find use in practicing the subject methods,as mentioned above. A kit can include one or more of the compositionsdescribed herein. A kit can include at least one nucleoside, nucleotide,polynucleotide, peptide, peptoid, saccharide, aptamer, or antibody orfragment thereof. A kit can include at least one binding moiety.

A kit can include a solid support. In some embodiments, the solidsupport is already functionalized with at least one molecule ofstructure I. In some embodiments, the solid support is alreadyfunctionalized with at least one nucleoside, nucleotide, polynucleotide, peptide, peptoid, saccharide, aptamer, or antibody orfragment thereof. A kit can include a reagent for coupling at least onenucleoside, nucleotide, polynucleotide, peptide, peptoid, saccharide,aptamer, or antibody or fragment thereof to the solid support.

The kit components may be present in separate containers, or one or moreof the components may be present in the same container, where thecontainers may be storage containers and/or containers that are employedduring the assay for which the kit is designed.

In addition to the above components, the subject kits may furtherinclude instructions for practicing the subject methods. Theseinstructions may be present in the subject kits in a variety of forms,such as printed information on a suitable medium or substrate (e.g., apiece or pieces of paper on which the information is printed), in thepackaging of the kit, in a package insert, etc. Yet another means wouldbe a computer readable medium (e.g., diskette, CD, etc.), on which theinformation has been recorded. Yet another means that may be present isa website address which may be used via the internet to access theinformation at a removed site.

Communicating a Result

Additional embodiments relate to the communication of assay results ordiagnoses or both to technicians, physicians or subjects, for example.In certain embodiments, computers will be used to communicate results ofthe assessing or diagnoses or both to interested parties, e.g.,physicians and their subjects. In some embodiments, the assessing can beperformed or results analyzed in a country or jurisdiction which differsfrom the country or jurisdiction to which the results or diagnoses arecommunicated. In some embodiments, a diagnosis based on the presence orabsence in a test subject of a binding moiety or a binding signature, orsignal identified may be communicated to the subject as soon as possibleafter the diagnosis is obtained. The diagnosis may be communicated tothe subject by the subject's treating physician. Alternatively, thediagnosis may be sent to a test subject by email or communicated to thesubject by phone. A computer may be used to communicate the diagnosis byemail or phone. In certain embodiments, the message containing resultsof a diagnostic test may be generated and delivered automatically to thesubject using a combination of computer hardware and software which willbe familiar to artisans skilled in telecommunications. In certainembodiments, all or some of the method steps, including the assaying ofsamples, diagnosing of diseases, and communicating of method results ordiagnoses, may be carried out in diverse (e.g., foreign) jurisdictions.

Other Embodiments

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.

It is to be understood that the methods and compositions describedherein are not limited to the particular methodology, protocols,constructs, and reagents described herein and as such may vary. It isalso to be understood that the terminology used herein is for thepurpose of describing particular embodiments only, and is not intendedto limit the scope of the methods and compositions described herein,which will be limited only by the appended claims. While preferredembodiments of the present disclosure have been shown and describedherein, it will be obvious to those skilled in the art that suchembodiments are provided by way of example only. Numerous variations,changes, and substitutions will now occur to those skilled in the artwithout departing from the disclosure. It should be understood thatvarious alternatives to the embodiments of the disclosure describedherein may be employed in practicing the disclosure. It is intended thatthe following claims define the scope of the disclosure and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

Several aspects are described with reference to example applications forillustration. Unless otherwise indicated, any embodiment can be combinedwith any other embodiment. It should be understood that numerousspecific details, relationships, and methods are set forth to provide afull understanding of the features described herein. A skilled artisan,however, will readily recognize that the features described herein canbe practiced without one or more of the specific details or with othermethods. The features described herein are not limited by theillustrated ordering of acts or events, as some acts can occur indifferent orders and/or concurrently with other acts or events.Furthermore, not all illustrated acts or events are required toimplement a methodology in accordance with the features describedherein.

Some inventive embodiments herein contemplate numerical ranges. Whenranges are present, the ranges include the range endpoints.Additionally, every sub range and value within the rage is present as ifexplicitly written out. The term “about” or “approximately” can meanwithin an acceptable error range for the particular value as determinedby one of ordinary skill in the art, which will depend in part on howthe value is measured or determined, e.g., the limitations of themeasurement system. For example, “about” can mean within 1 or more than1 standard deviation, per the practice in the art. Alternatively,“about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1%of a given value. Alternatively, particularly with respect to biologicalsystems or processes, the term can mean within an order of magnitude,within 5-fold, or within 2-fold, of a value. Where particular values aredescribed in the application and claims, unless otherwise stated theterm “about” meaning within an acceptable error range for the particularvalue can be assumed.

EXAMPLES Example 1—GPTMS-PAAm

FIG. 1 illustrates a GPTMS-PAAm molecule.

Example 2—GPTMS-TAEA

FIG. 2 illustrates a GPTMS-TAEA molecule.

Example 3—GPTMS-HMDA

FIG. 5 illustrates a GPTMS-HMDA molecule

What is claimed is:
 1. A molecule or salt thereof, having the structure:

wherein R¹ and R² are the same or different and are independentlyhydrogen, alkyl, alkenyl, aryl, heteroaryl, alkynyl, arylalkyl,arylalkenyl, haloalkyl, cycloalkyl, sulfonamidyl, acyl, or —CO₂R⁸,wherein R⁸ is alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, haloalkyl,cycloalkyl, cycloalkylalkyl, or arylcycloalkylalkyl; or wherein R¹ andR² and the N to which they are bound form a ring; or wherein at leastone of R¹ or R² comprise a nucleoside, nucleotide, polynucleotide,peptide, peptoid, saccharide, polysaccharide, aptamer, or antibody orfragment thereof; R³, oriented from N to X, is alkyl, heteroalkyl,amino-substituted alkyl, amino-substituted heteroalkyl, amidoalkyl,amidoheteroalkyl, amino-substituted amidoheteroalkyl, each optionallysubstituted with an alkyl, heteroalkyl, amino-substituted alkyl,amino-substituted heteroalkyl, amidoalkyl, amidoheteroalkyl, oramino-substituted amidoheteroalkyl; or wherein R³ is—(CR⁹R¹⁰CR¹¹R¹²)_(n)— wherein n is 1 to 100, and R⁹, R¹⁰, R¹¹, and R¹²are the same or different and are independently hydrogen, halo, alkyl,heteroalkyl, amino-substituted alkyl, amino-substituted heteroalkyl,amidoalkyl, amidoheteroalkyl, amino-substituted amidoheteroalkyl; orwherein R³ is

wherein n² and n⁴ are the same or different and are independently 1, 2,or 3, and n³ is 1 to 20; or wherein R³ is a polymer comprising alkyl,heteroalkyl, amino-substituted alkyl, aminoheteroalkyl, and amidoalkyl;X is O, NR¹³, or S, wherein R¹³ is hydrogen or alkyl; R⁴, oriented fromX to C, is alkyl, alkylether, and alkylthioether, wherein each of alkyl,alkylether, and alkylthioether is optionally substituted with hydroxyl,thiol, amino, or halo; R⁵, R⁶, and R⁷ are the same or different and areindependently hydrogen, alkyl, silyl, or siloxy; and wherein at leastone of R⁵, R⁶, or R⁷ optionally further comprises a solid phase.
 2. Themolecule or salt of claim 1, comprising a solid phase.
 3. The moleculeor salt of claim 2, wherein said solid phase comprises a silicon atom.4. A molecule or salt thereof having the structure:

wherein R¹ and R² are the same or different and are independentlyhydrogen, alkyl, alkenyl, aryl, heteroaryl, alkynyl, arylalkyl,arylalkenyl, haloalkyl, cycloalkyl, sulfonamidyl, acyl, or —CO₂R⁸,wherein R⁸ is alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, haloalkyl,cycloalkyl, cycloalkylalkyl, or arylcycloalkylalkyl; or wherein R¹ andR² and the N to which they are bound form a ring; or wherein at leastone of R¹ or R² comprise a nucleoside, nucleotide, polynucleotide,peptide, peptoid, saccharide, polysaccharide, aptamer, or antibody orfragment thereof; R³, oriented from NR¹R² to NH is alkyl, heteroalkyl,amino-substituted alkyl, amino-substituted heteroalkyl, amidoalkyl,amidoheteroalkyl, amino-substituted amidoheteroalkyl, each optionallysubstituted with an alkyl, heteroalkyl, amino-substituted alkyl,amino-substituted heteroalkyl, amidoalkyl, amidoheteroalkyl, oramino-substituted amidoheteroalkyl ; or wherein R³ is—(CR⁷R⁸CR⁹R¹⁰)_(n)—, wherein n is 1 to 100, and R⁷, R⁸, R⁹, and R¹⁰ arethe same or different and are hydrogen, halo, alkyl, heteroalkyl,amino-substituted alkyl, amino-substituted heteroalkyl, amidoalkyl,amidoheteroalkyl, amino-substituted amidoheteroalkyl; or wherein R³ is

wherein n² and n⁴ are the same or different and are independently 1, 2,or 3, and n³ is 1 to 20; or wherein R³ is a polymer or dendrimercomprising alkyl, heteroalkyl, amino-substituted alkyl,amino-substituted heteroalkyl, amidoalkyl, and amino-substitutedamidoalkyl, amidoheteroalkyl, or amino-substituted amidoheteroalkyl; R⁴,R⁵, and R⁶ are the same or different and are independently hydrogen,alkyl, silyl, or siloxy; (*) is a carbon center, wherein said carboncenter is in an R-configuration or S-configuration; and wherein at leastone of R⁴, R⁵, or R⁶ optionally further comprises a solid phase.
 5. Themolecule or salt of claim 4, wherein said carbon center is in anR-configuration.
 6. The molecule or salt of claim 4, wherein said carboncenter is in an S-configuration.
 7. The molecule or salt of any oneclaims 4 to 6, comprising said solid phase.
 8. The molecule or salt ofclaim 7, wherein said solid phase comprises a silicon atom.
 9. Themolecule or salt of any one of claims 4 to 8, wherein R³ is alkyl,aminoheteroalkyl, polyamidoaminoalkyl, or polyaminoalkyl.
 10. A moleculeor salt thereof having the structure:

wherein: n¹=1, 2, 3, 4, 5, 6, or 7; n² and n³ are the same or differentand are independently about 1 to about 1000; R¹, R², R³, R⁴, R⁵, R⁶, R⁷,R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ arethe same or different and are hydrogen, alkyl, alkenyl, aryl,heteroaryl, alkynyl, arylalkyl, arylalkenyl, haloalkyl, cycloalkyl,sulfonamidyl, acyl, or —CO₂R²⁴, wherein R²⁴ is alkyl, alkenyl, aryl,arylalkyl, arylalkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, orarylcycloalkylalkyl; or wherein R¹ and R² and the N to which they arebound, R³ and R⁴ and the N to which they are bound, R⁵ and R⁶ and the Nto which they are bound, R⁷ and R⁸ and the N to which they are bound, R⁹and R¹⁰ and the N to which they are bound, R¹¹ and R¹² and the N towhich they are bound, R¹³ and R¹⁴ and the N to which they are bound, R¹⁵and R¹⁶ and the N to which they are bound, R¹⁷ and R¹⁸ and the N towhich they are bound, and R¹⁹ and R²⁰ and the N to which they are boundindependently optionally form a ring; R³, R⁴, and R⁵ are the same ordifferent and are independently hydrogen, alkyl, silyl, or siloxy; (*),(**), and (***) are carbon centers, wherein said carbon centers areindependently in an R-configuration or S-configuration, or can beachiral centers; (****) is a second carbon center, wherein said secondcarbon center is in an R-configuration or S-configuration; and whereinat least one of R²¹, R²², or R²³ optionally further comprises a solidphase.
 11. The molecule of claim 10, wherein said carbon center is in anR-configuration.
 12. The molecule of claim 10, wherein said carboncenter is in an S-configuration.
 13. A molecule or salt of any one ofclaims 10 to 12, comprising a solid phase.
 14. A molecule or salt ofclaim 13, wherein said solid phase comprises a silicon atom.
 15. Amethod of synthesizing the molecule or salt of any one of claims 1 to14, comprising: a. forming an oxygen-silicon covalent bond between asolid substrate and a first molecule comprising: i. said silicon at afirst end and an epoxide, isocyanate, or thioisocyanate at a second end;b. forming a Y-carbon covalent bond between a carbon atom of saidepoxide, isocyanate, or thioisocyanate and a second molecule comprisingan amino group; wherein Y is nitrogen, oxygen, sulfur, or selenium;wherein said epoxide, isocyanate, or isothiocyanate and said silicon arelinked by a group comprising an alkyl, alkylether, or alkylthioether,wherein each of alky, alkylether, or alkylthioether is optionallysubstituted with hydroxyl, thiol, amino, or halo.
 16. The method ofclaim 15, wherein said second molecule is an alkylamine,heteroalkylamine, amino-substituted alkylamine, amino-substitutedheteroalkylamine, amidoalkylamine, amidoheteroalkylamine,amino-substituted amidoheteroalkylamine, each optionally substitutedwith an alkyl, heteroalkyl, amino-substituted alkyl, amino-substitutedheteroalkyl, amidoalkyl, amidoheteroalkyl, or amino-substitutedamidoheteroalkyl.
 17. The method of claim 15 or 16, wherein said formingan oxygen-silicon bond comprises a deposition reaction.
 18. The methodof claim 17, wherein said deposition reaction is performed in the gasphase.
 19. The method of claim 18, wherein said deposition reactioncomprises a chemical vapor deposition reaction.
 20. The method of claim19, wherein said chemical vapor deposition reaction occurs at anelevated temperature.
 21. The method of claim 20, wherein said elevatedtemperature is at least about 100° C., 110° C., 120° C., 130° C., 140°C., or 150° C.
 22. The method of any one of claims 15 to 21, whereinstep b further comprises the use of a diluent.
 23. The method of claim22, wherein said diluent is an alcohol.
 24. The method of claim 23,wherein said alcohol is isopropyl alcohol.
 25. The method of any one ofclaim 15 or 24, wherein said first molecule is3-glycidoxypropyltrimethoxysilane (GPTMS).
 26. The method of any one ofclaims 15 to 25, wherein said second molecule is ethylenediamine (EDA),(ethylenedioxy)bis(ethylamine) (EDBA), tris (2-aminoethyl)amine (TAEA),polyamidoamine (PAMAM), or polyallylamine (PAAm).
 27. The method ofclaim 26, wherein said second molecule is PAAm.
 28. The method of claim27, wherein said PAAm has an average molecular weight of from about 1KDa to about 100 KDa.
 29. The method of any one of claims 15 to 28,wherein said second molecule has a boiling point of from about 100° C.,to 300° C.
 30. The method of any one of claims 15 to 29, furthercomprising coupling said amino group to a protected amino acid or saltthereof.
 31. The method of claim 30, wherein said protected amino acidis a tert-butyl carbamate (Boc)- or 9-fluorenylmethyl carbamate(Fmoc)-protected amino acid.
 32. The method of claim 30 or 31, whereinsaid amino acid is glycine.
 33. An amino coating comprising two or moremolecules or salts of any one of claims 1 to
 14. 34. A method of tuningthe amino group density of the amino coating of claim
 33. 35. An arraycomprising at least 2 molecules or salts of any one of claims 1 to 14.36. The array of claim 35, wherein said array comprises a density ofsaid amino groups from about 1×10¹⁰ groups per cm² to about 1×10¹⁴groups per cm².
 37. The array of claim 35 or 36, wherein said moleculesor salts are stereoenriched or a racemate.
 38. The array of any one ofclaims 35 to 37, wherein said molecules or salts have an enantiomericexcess of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%,90%, 95%, 96%, 97%, 98%, 99%, or 100%.
 39. The array of any one ofclaims 35 to 38, wherein at least some of said molecules or their saltsform a coating, wherein said coating has a thickness of from about 1angstrom to about 25 angstroms.
 40. The array of any one of claims 35 to39, wherein said molecules or their salts are cross-linked.
 41. Thearray of any one of claims 35 to 40, further comprising instructions foruse.
 42. A method of making an array, comprising associating themolecule or salt of any one of claims 1 to 14 with a substrate.
 43. Amethod of making an array, comprising the method of any one of claims 20to
 32. 44. The method of claim 42 or 43, wherein said array comprises adensity of said amino groups from about 1×10¹⁰ groups per cm² to about1×10¹⁴ groups per cm².
 45. The method of any one of claims 42 to 44,comprising tuning the density of said amino groups on said array.
 46. Akit, comprising the molecule or salt of any one of claims 1 to 14 andinstructions for use.
 47. A kit, comprising the array of any one ofclaims 35 to 41 and instructions for use.
 48. The kit of claim 46 or 47,further comprising a binding moiety.
 49. The kit of claim 48, whereinsaid binding moiety comprises an antibody.
 50. The kit of claim 48 or49, wherein said binding moiety emits a signal.
 51. A method of making akit, comprising forming the kit with the molecule or salt of any one ofclaims 1 to
 14. 52. A molecule or salt thereof made by the process ofany one of claims 15 to
 32. 53. An array made by the process of any oneof claims 42 to 45.